These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 20419604

  • 1. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
    Tselis A.
    Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
    [Abstract] [Full Text] [Related]

  • 2. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
    Thöne J, Gold R.
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
    [Abstract] [Full Text] [Related]

  • 3. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J.
    Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
    [Abstract] [Full Text] [Related]

  • 4. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 5. Laquinimod in multiple sclerosis.
    Giacomini PS, Bar-Or A.
    Clin Immunol; 2012 Jan 22; 142(1):38-43. PubMed ID: 21450529
    [Abstract] [Full Text] [Related]

  • 6. Oral laquinimod treatment in multiple sclerosis.
    Fernández O.
    Neurologia; 2011 Mar 22; 26(2):111-7. PubMed ID: 21163185
    [Abstract] [Full Text] [Related]

  • 7. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A, Montalban X.
    Expert Rev Neurother; 2008 May 22; 8(5):699-714. PubMed ID: 18457527
    [Abstract] [Full Text] [Related]

  • 8. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
    Hainke U, Thomas K, Ziemssen T.
    Expert Opin Drug Metab Toxicol; 2016 Jun 22; 12(6):701-9. PubMed ID: 27089834
    [Abstract] [Full Text] [Related]

  • 9. Glatiramer acetate.
    Comi G, Moiola L.
    Neurologia; 2002 May 22; 17(5):244-58. PubMed ID: 12031214
    [Abstract] [Full Text] [Related]

  • 10. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
    Jolivel V, Luessi F, Masri J, Kraus SH, Hubo M, Poisa-Beiro L, Klebow S, Paterka M, Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F, Waisman A.
    Brain; 2013 Apr 22; 136(Pt 4):1048-66. PubMed ID: 23518712
    [Abstract] [Full Text] [Related]

  • 11. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
    Brück W, Zamvil SS.
    Expert Rev Clin Pharmacol; 2012 May 22; 5(3):245-56. PubMed ID: 22697588
    [Abstract] [Full Text] [Related]

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 22; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 13. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 22; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 18. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
    Constantinescu SE, Constantinescu CS.
    Expert Rev Clin Pharmacol; 2016 Nov 20; 9(1):49-57. PubMed ID: 26536299
    [Abstract] [Full Text] [Related]

  • 19. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action.
    Gold R, Linker RA, Stangel M.
    Clin Immunol; 2012 Jan 20; 142(1):44-8. PubMed ID: 21414846
    [Abstract] [Full Text] [Related]

  • 20. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 20; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.